ZURICH (Reuters) - Swiss medical device maker Synthes said on Monday that it could no longer sell or promote the use of its TFN products to treat intertrochanteric fractures in the United States.

Synthes has not had the best couple of weeks. The company, which is facing legal action from families whose loved ones died after receiving a Synthes bone cement product, is facing other ...

NEW YORK--(BUSINESS WIRE)--April 4, 2003--Spine Solutions, Inc. completed a previously announced $350 million merger agreement with Synthes-Stratec, Inc, Oberdorf, Switzerland. Synthes-Stratec is ...

SAN DIEGO —Treating impending pathologic femoral fractures using an expandable nail may reduce postop hospitalization and speed functional recovery, according to a study presented here. Researchers ...